DFW

PATENT
675301-2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	PEYMAN
Serial No.	:	10/828,982
For	:	OCULAR THERAPY WITH REDUCED OCULAR NEOVASCULARIZATION
Filed	:	April 21, 2004
Examiner	:	TBA
Art Unit	:	1614

745 Fifth Avenue
New York, NY 10151

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Mail Stop, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**, on **March 15, 2005**.

Thomas J. Kowalski, Reg. No. 32,147
(Name of Applicant, Assigned or Registered Representative)

Signature

March 15, 2005
Date of Signature

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully direct the Examiner's attention to the documents listed on the accompanying PTO-1449 form, and which are enclosed herewith.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits. Accordingly, it is believed that no fee is required. However, the Commissioner is authorized to charge any additional fee, or to credit any overpayment in fees, to Deposit Account No. 50-0320.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

Consideration of this Information Disclosure Statement is respectfully requested.

Applicants respectfully request that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicant

By: _____

Thomas J. Kowalski
Reg. No. 32,147
Tel. No. (212) 588-0800

Based on Form PTO-1449 (3/90)	ATTY. DOCKET NO.	SERIAL NO.
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	675301-2002	10/828,982
	APPLICANT: Peyman	
	FILING DATE: April 21, 2004	GROUP: 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,011,023	01-2000	Clark, et al.			
	AB	4,079,038	03-1978	Choi, et al.			
	AC	4,093,709	06-1978	Choi, et al.			
	AD	4,131,648	12-1978	Choi, et al.			
	AE	4,138,344	02-1979	Choi, et al.			
	AF	4,180,646	12-1979	Choi, et al.			
	AG	4,304,767	12-1981	Heller, et al.			
	AH	4,946,931	08-1990	Heller, et al.			
	AI	5,968,543	10-1999	Heller, et al.			
	AJ	6,413,536	07-2002	Gibson, et al.			
	AK	6,596,296	07-2003	Nelson, et al.			
	AL	6,613,355	09-2003	Ng, et al.			
	AM	6,667,371	12-2003	Ng, et al.			
	AN	5,770,589	06-1998	Billson, et al.			
	AO	6,395,294	05-2002	Peyman, et al.			
	AP	2003/0027790	02-2003	Singh, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ		Ashton et al., Effect of Cortisone on Vascularization and Opacification of the Cornea Induced by Alloxan, Brit J Ophthal, 35:718-724 (1951).
	AR		Bressler et al., Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin, Arch Opthalmol 1999; 117:1329-1345. (no copy, cite to 10/886,409 9/24/04 IDS)
	AS		Calabresi et al., Antineoplastic Agents, Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eight Edition, Pergamon Press, New York, 1990, Chap. 52, pp. 1209-1263. (no copy, cite to 10/886,409 9/24/04 IDS)

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)	ATTY. DOCKET NO.	SERIAL NO.
	675301-2002	10/828,982
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	
	Peyman	
	FILING DATE	GROUP
	April 21, 2004	1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AT		Chang et al., Corneal neovascularization, Current Opinion in Ophthalmology, 12:242-249 (2001)
	AU		Crum et al., A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment, Science, 230:1375-8 (Dec 20, 1985).
	AV		Dana et al., Loss and Restoration of Immune Privilege in Eyes with Corneal Neovascularization, Investigative Ophthalmology & Visual Science, Vol.37, No.12:2486-2494 (Nov 1996).
	AW		Deutsch et al., Suppressive Effects of Indomethacin on Thermally Induced Neovascularization of Rabbit Corneas, Amer J Ophthalmology, 87:536-540 (1979).
	AX		Ezra, Neovasculogenesis. Triggering Factors and Possible Mechanisms, Survey of Ophthalmology, Vol.24, No.3:167-176 (Nov-Dec 1979).
	AY		Ezra et al., Topical Formulations of Novel Angiostatic Steroids Inhibit Rabbit Corneal Neovascularization, Investigative Ophthalmology & Visual Science, Vol.38, No.10: 1954-1962 (Sep 1997).
	AZ		Fife et al., Effects of Tetracyclines on Angiogenesis In Vitro, Cancer Letters, 153:75-78 (2000).
	BA		Folkman et al., Angiogenesis, J Biol Chem, 267: 10931-10934 (1992).
	BB		Franklin et al., Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit J Surgery, 86:771-775 (1999).
	BC		Golub et al., Tetracyclines Inhibit Connective Tissue Breakdown: New Therapeutic Implications for an Old Family of Drugs, Critical Reviews in Oral Biology and Medicine, 2(2):297-322 (1991).
	BD		Hanemaaijer et al., Inhibition of MMP Synthesis by Docycycline and Chemically Modified Tetracyclines (CMTs) in Human Endothelial Cells, Adv Dent Res, 12:114-118 (Nov 1998).
	BE		Harris et al., Implantation of a Sustained-Release Ganciclovir Implant, Chapter 45 of Vitreoretinal Surgical Techniques, Eds. Peyman, Meffert, Conway, and Chou, Martin Dunitz Ltd. (2001).
	BF		Jayson et al., Heparin Oligosaccharides: Inhibitors of the Biological Activity of bFGF on Caco-2 Cells, Brit J Cancer, 75(1):9-16 (1997).
	BG		Joussen et al., Topical Application of Methotrexate for Inhibition of Corneal Angiogenesis, Graefe's Arch Clin Exp Ophthalmol, 237:920-927 (1999).
	BH		Lepri et al. Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization, J Ocular Pharmacology, Vol.10, No.1:273-280 (1994).
	BI		Liu et al., A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent, Antimicrobial Agents and Chemotherapy, Vol.46 No.5:1447-1454 (May 2002).
	BJ		Mahoney et al., Dosing Effects on the Neovascularization Response to Silver Nitrate Cauterization of the Rat Cornea, Current Eye Research, Vol.4, No.5:531-535 (1985).
	BK		Nikolic et al., Inhibition of Vascularization in Rabbit Corneas by Heparin: Cortisone Pellets, Investigative Ophthalmology & Visual Science, Vol.27/4:449-456 (April 1986).
	BL		Peyman et al., Eds., Vitreoretinal Surgical Techniques, Martin Dunitz, London, 2001, Chapter 45.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)	ATTY. DOCKET NO.	SERIAL NO.
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	675301-2002	10/828,982
	APPLICANT: Peyman	
	FILING DATE: April 21, 2004	GROUP: 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BM		Phillips et al., Effects of Prednisolone and Medroxyprogesterone on Corneal WOund Healing, Ulceration, and Neovascularization, Arch Ophthalmol, Vol.101:640-643 (1983).
	BN		Proia et al., The Effect of Angiostatic Steroids and B-Cyclodextrin Tetradecasulfate on Corneal Neovascularization in the Rat, Exp Eye Res, 57:693-698.
	BO		Seftor et al., Targeting the Tumor Microenvironment with Chemically Modified Tetracyclines: Inhibition of Laminin 5 γ2 Chain Promigratory Fragments and Vasculogenic Mimicry, Molecular Cancer Therapeutics, Vol.1:1173-1179 (Nov 2002).
	BP		Smorenburg et al., The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies, Pharm Reviews, Vol.53, No.1:93-105 (2001).
	BQ		Sorsa et al., Functional Sites of Chemically Modified Tetracyclines: Inhibition of the Oxidative Activation of Human Neutrophil and chicken Osteoclast Pro-matrix Metalloproteinases, J Rheumatology, 25(5):975-982 (1998).
	BR		Totan et al., Effect of Caffeic Acid Phenethyl Ester on Corneal Neovascularization in Rats, Current Eye Research, Vol.23, No.4:291-297 (2001).
	BS		Wise DL, Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, Inc. New York, pp. 108-119, 155-285, 510-516 (2000).
	BT		Danis et al., *Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide*, Ophthalmology, (1996), 103:2099-2104.
	BU		Jonas et al., *Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone*; J Glaucoma, (2001), 10:284-287.
	BV		Jonas et al., *Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy*; Amer J Ophthalmol, (2001), 131:468-471.
	BW		Jonas et al., *Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony*; Graefe's Arch Clin Exp Ophthalmol, (2001), 239:464-465.
	BX		Jonas et al., *Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularisation*; J Cataract Refract Surg, (2002), 28:2040-2041.
	BY		Jonas et al., *Intravitreal injection of triamcinolone for diffuse diabetic macular edema*; Archives of Ophthalmol, (Jan 2003), 121:57-61.
	BZ		Jonas et al., *Intraocular pressure after intravitreal injection of triamcinolone acetonide*; Br J Ophthalmol, (Jan 2003), 87:24-27.
	CA		McCuen II et al., *The lack of toxicity of intravitreally administered triamcinolone acetonide*, Amer J Ophthalmol, (1981), 91:785-788.
	CB		Peyman et al., *Triamcinolone acetonide as an aid to visualization of the vitreous and the posterieor hyaloid during pars plana vitrectomy*, Retina, (2000), 20:554-555.
	CC		Sakamoto et al., *Optic disk cup filled with triamcinolone*, Retina, (2002), 22:516-518.
	CD		Wilson et al., *Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation*, Arch Ophthalmol, (1992), 110:1155-1159.
	CE		

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.